Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    P16 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced NSCLC

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P16.02 - Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience

      00:00 - 00:00  |  Presenter: Samantha Larna Dean

      • Abstract

      Loading...

  • +

    ES02 - Multidisciplinary Collaboration in the Treatment of Oligometastatic Disease*

    • 08:15 - 08:50
    • 9/10/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Education Session
    • Track: Multimodality of Advanced Lung Cancer
    *Full-length Educational talk will be available as pre-release content as of September 1. The Live Day Educational Sessions will feature brief summaries and extended live discussion with the presenters. Delegates are encouraged to watch the pre-released content prior to watching the live Educational Sessions.
    • +

      ES02.04 - Systemic Therapy Influenced Trials in Oligometastatic Disease

      08:21 - 08:23  |  Presenter: Paul Leslie Ross Mitchell

      • Abstract

      Loading...

  • +

    OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation

    • 18:45 - 19:45
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      OA15.02 - Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations

      18:55 - 19:05  |  Presenter: Pasi A. Janne

      • Abstract

      Loading...